Ipamorelin + Tesamorelin is a vendor blend pairing a stabilized GHRH analog with a selective ghrelin-receptor secretagogue. There are no dedicated trials of the blend, so this page describes hypothesized effects extrapolated from the components. It is not an FDA-approved product.
Overview
This blend pairs two growth-hormone-axis peptides that act at different receptors. The rationale is that stimulating both the GHRH pathway and the ghrelin-receptor pathway at once could provide a complementary signal. Interest centers on:
- Supporting the body's own pulsatile GH release rather than injecting GH.
- Combining an upstream GHRH analog with a downstream secretagogue.
- Downstream effects on IGF-1 that mediate much of GH's action.
These are the mechanisms researchers study for the individual peptides; they are not a validated result for the combined blend.
Complementary GH signaling
The central idea behind pairing these peptides is that they act on separate parts of the same system. GHRH-analog signaling and ghrelin-receptor signaling are often described as complementary, and combining them is hypothesized to produce a fuller GH pulse than either alone. This is a conceptual argument drawn from how each pathway works, not a demonstrated advantage of the blend.
What each component contributes
The two peptides bring different profiles:
- Tesamorelin — a stabilized GHRH analog with a studied, approved use in HIV-associated visceral fat accumulation.
- Ipamorelin — a selective secretagogue noted for relatively little effect on prolactin and cortisol.
Any benefit attributed to the blend leans on this component-level knowledge rather than on trials of the pairing itself.
How the blend compares to related approaches
This blend sits among other GH-axis strategies:
- CJC-1295 + ipamorelin — another GHRH-analog-plus-secretagogue pairing discussed similarly.
- Single-agent tesamorelin — the only component with a specific approved indication.
- Other secretagogues — such as GHRP-2 or GHRP-6, which are less selective than ipamorelin.
The distinguishing claim for this blend is complementary dual-pathway signaling, which remains conceptual.
Evidence and caveats
The blend is discussed enthusiastically, but interest is not proof of benefit. Key caveats:
- There are no dedicated trials of the combination; evidence is extrapolated.
- The blend is not FDA-approved, though tesamorelin alone has an approved use.
- Both components are prohibited at all times under WADA rules.
- Raising GH/IGF-1 does not guarantee any desired downstream outcome.